| Literature DB >> 36080235 |
Cristóbal Balada1, Valentina Díaz1, Mónica Castro2, Macarena Echeverría-Bugueño3,4, María José Marchant1, Leda Guzmán1.
Abstract
Microsorum scolopendia (MS), which grows on the Chilean island of Rapa Nui, is a medicinal fern used to treat several diseases. Despite being widely used, this fern has not been deeply investigated. The aim of this study was to perform a characterization of the polyphenolic and flavonoid identity, radical scavenging, antimicrobial, and anti-inflammatory properties of MS rhizome and leaf extracts (RAE and HAE). The compound identity was analyzed through the reversed-phase high-performance liquid chromatography (RP-HPLC) method coupled with mass spectrometry. The radical scavenging and anti-inflammatory activities were evaluated for DPPH, ORAC, ROS formation, and COX inhibition activity assay. The antimicrobial properties were evaluated using an infection model on Human Dermal Fibroblast adult (HDFa) cell lines incubated with Staphylococcus aureus and Staphylococcus epidermidis. The most abundant compounds were phenolic acids between 46% to 57% in rhizome and leaf extracts, respectively; followed by flavonoids such as protocatechic acid 4-O-glucoside, cirsimaritin, and isoxanthohumol, among others. MS extract inhibited and disaggregated the biofilm bacterial formed and showed an anti-inflammatory selective property against COX-2 enzyme. RAE generated a 64% reduction of ROS formation in the presence of S. aureus and 87.35% less ROS in the presence of S. epidermidis on HDFa cells. MS has great therapeutic potential and possesses several biological properties that should be evaluated.Entities:
Keywords: Matu’a Pua’a; Rapa Nui; anti-inflammatory; antioxidant; flavonoids; polyphenols
Mesh:
Substances:
Year: 2022 PMID: 36080235 PMCID: PMC9457714 DOI: 10.3390/molecules27175467
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.927
Weight of extracts from MS samples.
| Scheme | % Yield | Weight of Extract Obtained (mg/g) |
|---|---|---|
| RAE | 1.19 | 1.53 |
| HAE | 20.77 | 2.71 |
Total polyphenols and flavonoids in MS extracts.
| Sample | Total Polyphenols (mg GAE/g Dry Sample) | Total Flavonoids (mg KE/g Dry Sample) |
|---|---|---|
| RAE | 57.13 ± 0.81 | 29.01 ± 0.65 |
| HAE | 14.77 ± 0.52 | 10.58 ± 0.56 |
Figure 1Relative distribution n of polyphenol families in MS extracts from (A) RAE, (B) HAE (unit: %).
Relative abundances of compounds in MS extracts.
| Relative Abundance (%) | ||||
|---|---|---|---|---|
| Compound | Family | Mode | RAE | HAE |
| Protocatechuic acid 4-O-glucoside | Phenolic acid | + | 1.78 | 2.19 |
| p-Coumaroyl tartaric acid | − | NA | 28 | |
| Feruloyl tartaric acid | − | NA | 12.8 | |
| Kaempferol 3-O-glucuronide | Flavonoid | + | NA | 1.41 |
| Cirsimaritin | − | 8.45 | NA | |
| Kaempferide | − | 0.47 | NA | |
| Isoxanthohumol | − | 9.09 | NA | |
| Daidzein | − | NA | 10.85 | |
| Daidzin | − | 0.37 | 2.19 | |
| Resveratrol | Stilbene | + | 0.13 | 1.23 |
| Pyrogallol | Others | + | 9.32 | 1.81 |
| Catechol | + | 3.16 | 2.82 | |
| 1,4-Naphthoquinone | + | 0.34 | NA | |
NA: Not among the most abundant in the extract.
Radical scavenging capacity of MS extracts by DPPH and ORAC assays.
| Sample | DPPH (% Inhibition) | ORAC |
|---|---|---|
| RAE | 82.96 ± 0.53 | 1.63 ± 0.02 |
| HAE | 49.16 ± 1.18 | 1.54 ± 0.14 |
| Gallic acid | 79.24 ± 0.26 | 1.03 ± 0.14 |
| Vitamin C | 70.45 ± 1.34 | 0.52 ± 0.04 |
| TROLOX | - | 1 |
A concentration of 20 µg/mL of RAE, HAE, Gallic acid, Vitamin C and TROLOX was used to perform the DPPH and ORAC assays.
SPF measured in MS extracts.
| Sample | SPF Detected | SPF Equivalent | SPF Level |
|---|---|---|---|
| RAE | 17.99 ± 0.02 | 15 | Moderate |
| HAE | 21.91 ± 0.38 | 20 | Moderately high |
Minimum 80% inhibitory concentrations of MS extracts in S. aureus and S. epidermidis.
|
|
| |||
|---|---|---|---|---|
| Sample | MIC80 (µg/mL) | Category | MIC80 (µg/mL) | Category |
| RAE | 512< | Resistant | 128 | Resistant |
| HAE | 512< | Resistant | 512 | Resistant |
| Kanamycin | 2 | Susceptible | 512< | Resistant |
| Chloramphenicol | 4 | Susceptible | 16 | Intermediate susceptibility |
Figure 2Biofilm formation inhibition and disruption assay for S. aureus and S. epidermidis. (A) RAE treatment against S. aureus. (B) RAE treatment against S. epidermidis (C) HAE treatment against S. aureus. (D) HAE treatment against S. epidermidis. **** indicates p ≤ 0.0001 between no treatment control and the treated bacteria.
IC50 and selectivity indices of MS extracts on COX enzymes.
| IC50 (µg/mL) | |||
|---|---|---|---|
| Sample | COX-1 | COX-2 | Selectivity Index |
| RAE | 31.28 ± 0.39 | 3.14 ± 0.02 | 9.96 |
| HAE | 24.08 ± 1.41 | 3.52 ± 0.01 | 6.84 |
| SC560 | 6.54 × 10−3 ± 9.02 × 10−5 | - | - |
| Celecoxib | - | 1.81 ± 0.02 | - |
Figure 3Viability of HDFa cells exposed to MS extracts at concentrations of 1 µg/mL to 100 µg/mL for 24 h. These results prompted us to use the RAE and HAE extracts at concentrations between 63 and 100 µg/mL for infection assays on HDFa cells.
Figure 4Lactate Dehydrogenase release. (A) HDFa cells exposed to an MOI of 5 S. aureus and different concentrations of the RAE and HAE extracts at 6 h post infection. (B) HDFa cells exposed to an MOI of 5 S. epidermidis and different concentrations of the RAE and HAE extracts at 6 h post infection. **** indicates p ≤ 0.0001 between the respective control of untreated cells and the treated cells.
Figure 5Percentage of reactive oxygen species. (A) HDFa cells exposed to MS extracts for 3 h. (B) Simultaneous exposure for 3 h to S. aureus and different concentrations of MS extracts. (C) Pretreatment for 3 h with different concentrations of MS extracts, and subsequent incubation for 3 h with S. aureus. (D) HDFa cells exposed for 3 h to S. epidermidis and different concentrations of MS extracts. (E) HDF cells pretreated for 3 h with different concentrations of MS extracts and subsequently incubated for 3 h with S. epidermidis. **** indicates p ≤ 0.0001 between the respective control of untreated cells and the treated cells.